Navigation Links
Labtec’s Next Generation Pain Patch Successful in Clinical,Studies

LANGENFELD, Germany, April 25, 2007-Labtec GmbH (Langenfeld, Germany), a specialty pharmaceutics company announces positive results from a multiple dose clinical study for their proprietary Sufentanil transdermal patch.

“Today, we are pleased to announce the successful completion of the second clinical trial for our Sufentanil TDS®. Our goal for this program was to complete this study in the first half of 2007,” says Dr. Armin Breitenbach, Labtec's Director of Pharmaceutical Development. “Based on the positive results of the first Phase I trial for our Sufentanil patch that showed good safety, tolerability and extended drug release, we initiated this trial end of last year. The objectives to demonstrate effective plasma levels and safety of repetitive applications of our Sufentanil patch were fully met. We believe that this product, once approved, will provide a significant improvement over currently available pain management therapies on the market today.”

Labtec's transdermal Sufentanil product is intended to provide extended chronic pain relief for several days. The patch is not only very small but at the same time has an unusually low drug content. The proprietary formulation releases the drug with an unparalleled efficiency. Additional patient comfort is achieved by the use of a special non-woven backing. Unlike most backing films used in transdermal systems, this material is non-occlusive, allows the skin to breathe and maintains its integrity throughout the application period.

“After the huge success story of our Fentanyl patch, which is marketed by our licensee ratiopharm and several other leading generic companies in Europe, we are looking forward to see our Sufentanil TDS® move forward. In our opinion this transdermal patch is the logical next generation product for severe chronic pain. Sufentanil is one of the most potent drugs in its class, seven times more potent than Fentanyl and at the same time offers various advantages in terms of safety and efficacy for chronic pain treatment with a transdermal system” says Labtec’s Managing Director, Dr. Ingo Lehrke.

Beginning with phase II clinical development Labtec is now willing to enter into a global development and licensing agreement with a strong and committed partner.

Company Information:
Labtec GmbH is a leading drug delivery company specialised on development of matrix-type transdermal and topical patches as well as fast dissolving oral films (Rapidfilms).

Contact:
Dr. Ingo Lehrke; Managing Director; Business Development & Licensing
Labtec GmbH | www.labtec-pharma.com | Raiffeisenstrasse 3a | D-40764 Langenfeld | Germany | T: +49 2173 9735-0


'"/>




Related medicine technology :

1. Positive Results for Second-Generation Taxus Liberte Coronary Stent System Highlighted in Journal of American College of Cardiology
2. Kosan Presents Promising Phase 1 Data on Second-Generation Hsp90 Inhibitor, Alvespimycin, Showing Antitumor Activity in Refractory Breast and Ovarian Cancers at ASCO
3. Medtronic Announces Positive Nine-Month Results for Endeavor Resolute Next Generation Drug-Eluting Stent at EuroPCR
4. Kosan Presents Preclinical Antitumor and Safety Data On Next-Generation Epothilone KOS-1803 at AACR
5. CeNeRx BioPharma Announces Positive Phase I Results in First Human Trial of Third Generation RIMA Antidepressant
6. Iomai Dose-Ranging Trial Demonstrates Needle-Free Patch Vaccine for Travelers Diarrhea Stimulates Immune Response Even at Low Doses
7. Speedel Reports Successful SPP635 Phase IIa Trial in Hypertension
8. Pieris Progresses Development of its Proprietary Biotherapeutics Platform: Successful Demonstration of Dual Targeting With Duocalin(R) Technology
9. Modigene Announces Successful Completion of Pharmacokinetic & Pharmacodynamic Pre-Clinical Experiments for Proprietary Long-Acting Human Growth Hormone, Long-acting Interferon Beta and Long-acting Erythropoietin
10. Second Successful Quigley QR-443 Study Suggests Method of Action Relevant to Broad Range of Chronic Inflammatory Diseases - Human Study to Follow -
11. Javelin Pharmaceuticals Announces Successful Pivotal Phase 3 Trial Data
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/14/2017)... 14, 2017  Johnson & Weaver, LLP announces that a ... Zimmer Biomet Holdings, Inc. (NYSE: ZBH )  securities ... 2016 (the "Class Period"). Zimmer Biomet provides musculoskeletal ... reconstructive products, such as knee and hip reconstructive products. ... According to ...
(Date:1/13/2017)... New York , January 13, 2017 ... rising prevalence of AIDS will collectively contribute to the demand ... expected to reach a value of US$ 551.0 Mn by ... will remain the most lucrative markets for western blotting, ... lead the market globally. ...
(Date:1/13/2017)... , January 13, 2017 This ... see how they have fared at yesterday,s closing bell: ... Biopharma Inc. (NASDAQ: GALE ), and ACADIA ... harness cellular and biomolecular processes to develop technologies and ... environmental footprint, feed the hungry, use less and cleaner ...
Breaking Medicine Technology:
(Date:1/15/2017)... ... 2017 , ... "On Tour is a music themed slideshow production package which ... Austin - CEO of Pixel Film Studios. , On Tour’s new slide presets ... animation of their slideshows. Place each slide on top of another slide or piece ...
(Date:1/14/2017)... MN (PRWEB) , ... January 14, 2017 , ... ... present the distinctions among their expanding line of activated charcoal products. With more ... the importance of categorizing their products according to how they cater to specific ...
(Date:1/13/2017)... ... ... The 18th European Congress: Perspectives in Lung Cancer will be held in ... is expertly designed to meet the educational needs of European oncology clinicians and researchers ... Dr. Giorgio V. Scagliotti, Professor of Oncology at the University of Torino, and organized ...
(Date:1/13/2017)... ... January 13, 2017 , ... An inventor from Virginia Beach, Va., is always ... order to diversify my outfits, so he decided to design something that enhances the ... the appearance of a belt to allow for quick, easy changing of its look. ...
(Date:1/13/2017)... , ... January 13, 2017 , ... MyGenetx, a molecular ... Communications, and Sales Administration Specialist, Mary Taylor Smith, RD, LD, will serve on the ... serving one year as a board member and one year as Vice President. She ...
Breaking Medicine News(10 mins):